Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF222 divergent transcript (ZNF222-DT) refers to a long non-coding RNA that is transcribed in the divergent (antisense) direction from the promoter region of the ZNF222 gene, a member of the C2H2 zinc finger transcription factor family. Divergent transcripts are commonly found at promoters of transcriptional regulators and developmental genes and are characterized by specific promoter architecture, such as large CpG islands, high conservation, distinct histone marks (H3K79me2), and bidirectional RNA polymerase II recruitment. While divergent lncRNAs are implicated in fine-tuning transcriptional regulation and chromatin states, there is currently no evidence that ZNF222-DT itself is a therapeutic target, nor are there known drugs, biomarker uses, or direct disease associations for this specific transcript[2]. No information supports its classification as a receptor, enzyme, transporter, or other typical drug target class.
lncRNAs often act in chromatin modification, transcriptional regulation, or RNA–protein scaffolding, but specific function of ZNF222-DT is unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF222 divergent transcript (ZNF222-DT).